Stocks › RGNX
REGENXBIO Inc.
RGNX·Nasdaq·
United States·USD
$7.16
-0.02 (-0.28%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
RGNX
REGENXBIO Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
RGNXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of RGNX by members of U.S. Congress · 2 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Peter WelchHouse · D · VT |
RGNXREGENXBIO Inc. · Stock |
Purchase $1,001 - $15,000 |
Nov 14, 2019 | Oct 22, 2019 | Filing ↗ |
Peter WelchHouse · D · VT |
RGNXREGENXBIO Inc. · Stock |
Sale $1,001 - $15,000 |
Nov 14, 2019 | Nov 8, 2019 | Filing ↗ |
Whale Activity
Position changes in RGNX reported for 2026-09-30 by 195 institutional filers
- Increased74
- New33
- Held21
- Decreased39
- Closed22
- No prior filing6
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 7.7M | $57.8M | increased |
| Redmile Group, LLC | 5.0M | $38.0M | increased |
| JPMORGAN CHASE & CO | 3.6M | $26.5M | increased |
| STATE STREET CORP | 3.2M | $23.7M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.6M | $19.9M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.5M | $19.0M | increased |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.9M | $14.5M | increased |
| TWO SIGMA INVESTMENTS, LP | 1.9M | $14.3M | increased |
| MORGAN STANLEY | 1.8M | $13.7M | decreased |
| GOLDMAN SACHS GROUP INC | 1.7M | $12.7M | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 1.6M | $11.9M | increased |
| AQR CAPITAL MANAGEMENT LLC | 1.4M | $10.3M | decreased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by RGNX insiders, by quarter · Form 4
Recent Insider Transactions
766 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Malzahn CraigChief Technology Officer | Tax withholding | −234 | $9.32 | $2K | Sep 1, 2026 | Form 4 ↗ |
| Chan MitchellChief Financial Officer | Tax withholding | −4,902 | $9.32 | $46K | Sep 1, 2026 | Form 4 ↗ |
| Ciongoli Gregory AustinDirector | Purchase | +53.4K | $9.36 | $500K | Aug 27, 2026 | Form 4 ↗ |
| Ciongoli Gregory AustinDirector | Purchase | +49.2K | $9.14 | $450K | Aug 26, 2026 | Form 4 ↗ |
| Ciongoli Gregory AustinDirector | Grant / award | +15.4K | $0.00 | $0 | Aug 25, 2026 | Form 4 ↗ |
| PAKOLA STEVEChief Medical Officer | Tax withholding | −7,468 | $9.69 | $72K | Aug 1, 2026 | Form 4 ↗ |
| Christmas Patrick J.Chief Strategy & Legal Officer | Tax withholding | −4,699 | $9.69 | $46K | Aug 1, 2026 | Form 4 ↗ |
| PAKOLA STEVEChief Medical Officer | Sale | −2,161 | $13.64 | $29K | Jul 2, 2026 | Form 4 ↗ |
| PAKOLA STEVEChief Medical Officer | Option exercise | +2,161 | $7.86 | $17K | Jul 2, 2026 | Form 4 ↗ |
| Simpson CurranChief Executive Officer · Director | Tax withholding | −6,818 | $13.09 | $89K | Jul 1, 2026 | Form 4 ↗ |
| PAKOLA STEVEChief Medical Officer | Sale | −36.7K | $12.86 | $472K | Jul 1, 2026 | Form 4 ↗ |
| PAKOLA STEVEChief Medical Officer | Option exercise | +36.7K | $7.86 | $289K | Jul 1, 2026 | Form 4 ↗ |
| Simpson CurranChief Executive Officer · Director | Grant / award | +1,453 | $10.18 | $15K | Jun 30, 2026 | Form 4 ↗ |
| PAKOLA STEVEChief Medical Officer | Sale | −19.6K | $11.04 | $216K | Jun 29, 2026 | Form 4 ↗ |
| Bennett JeanDirector | Grant / award | +9,807 | $0.00 | $0 | May 29, 2026 | Form 4 ↗ |
| Zachary JenniferDirector | Grant / award | +9,807 | $0.00 | $0 | May 29, 2026 | Form 4 ↗ |
| Glucksmann AlexandraDirector | Grant / award | +9,807 | $0.00 | $0 | May 29, 2026 | Form 4 ↗ |
| Fox Allan M.Director | Grant / award | +9,807 | $0.00 | $0 | May 29, 2026 | Form 4 ↗ |
| Mills Kenneth T.Director | Grant / award | +9,807 | $0.00 | $0 | May 29, 2026 | Form 4 ↗ |
| Tasse DanielDirector | Grant / award | +9,807 | $0.00 | $0 | May 29, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding RGNX · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 2.0M | $23.5M | 0.22% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.5M | $17.9M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 1.3M | $15.2M | 0.02% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund TIAA-CREF Funds | 855.2K | $8.3M | 0.20% | Jul 31, 2026 |
| JPMorgan Small Cap Growth Fund JPMorgan Trust II | 629.8K | $7.5M | 0.29% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 564.5K | $6.8M | 0.01% | Jun 30, 2026 |
| VANGUARD STRATEGIC SMALL-CAP EQUITY FUND VANGUARD HORIZON FUNDS | 467.2K | $5.6M | 0.18% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 527.9K | $5.1M | 0.02% | Jul 31, 2026 |
| BlackRock Advantage Small Cap Core Fund BlackRock Funds | 537.0K | $5.1M | 0.09% | Aug 31, 2026 |
| iShares Russell 2000 Growth ETF iShares Trust | 378.1K | $4.5M | 0.03% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list RGNX's shares (CUSIP 75901B107), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 3.2M shares4.8%
Nov 10, 2026 · ↗ - JPMORGAN CHASE & CO.SCHEDULE 13G · passive (13G) · 3.6M shares5.3%
Oct 13, 2026 · ↗ - JPMORGAN CHASE & COSCHEDULE 13G/A · passive (13G) · 2.3M shares4.4%
Jun 4, 2026 · ↗ - STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 2.7M shares5.3%
May 12, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming regenxbio as client
- BGR GOVERNMENT AFFAIRSREGENXBIO INC. · 2026 Q4 · HCR—
Filing ↗ - THEGROUP DC, LLCREGENXBIO · 2026 Q3 · HCR$60K
Filing ↗ - DLA PIPER LLP (US)REGENXBIO INC. · 2026 Q3 · HCR, MED$40K
Filing ↗ - LMH STRATEGIC SOLUTIONSREGENXBIO INC. · 2026 Q3 · HCR, PHA$60K
Filing ↗ - THEGROUP DC, LLCREGENXBIO · 2026 Q2 · HCR$60K
Filing ↗
Government Contracts
Federal awards to REGENXBIO Inc. · USAspending
No federal contract awards found for REGENXBIO Inc..
U.S. Patents
Recent USPTO applications naming REGENXBIO Inc.
No USPTO patent applications found for REGENXBIO Inc..
Annual Financials
From RGNX's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $170.4M | $83.3M | $90.2M | $112.7M | $470.3M |
| Operating income | -$161.2M | -$233.3M | -$268.1M | -$262.9M | $160.0M |
| Net income | -$193.9M | -$227.1M | -$263.5M | -$280.3M | $127.8M |
| Diluted EPS | -$3.76 | -$4.59 | -$6.02 | -$6.50 | $2.91 |
| Operating cash flow | -$124.0M | -$173.1M | -$218.4M | -$207.5M | $218.9M |
| Cash and equivalents | $34.5M | $57.5M | $34.5M | $97.0M | $345.2M |
| Total assets | $453.0M | $466.0M | $574.0M | $833.3M | $1.11B |
| Total liabilities | $350.3M | $206.3M | $262.2M | $317.1M | $349.6M |
| Shareholders' equity | $102.7M | $259.7M | $311.7M | $516.2M | $764.3M |
As REGENXBIO Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 5, 2026 ↗
Stock Splits
Every split and reverse split in the price history
No stock splits in RGNX's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 2.02, 9.01Results of operationsNov 5, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeOct 16, 2026
EDGAR ↗ - 8-K · Items 1.01Material agreementSep 23, 2026
EDGAR ↗ - 8-K · Items 5.02, 9.01Officer / director changeAug 25, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsAug 24, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 6, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsJul 20, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsJun 29, 2026
EDGAR ↗ - 8-K · Items 5.07, 8.01Shareholder vote · Other eventsJun 3, 2026
EDGAR ↗ - 8-K · Items 2.02, 7.01, 8.01, 9.01Results of operations · Reg FD disclosure · Other eventsMay 14, 2026
EDGAR ↗
About REGENXBIO Inc.
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersROCKVILLE, MD
SEC CIK0001590877 ↗
Former namesReGenX Biosciences, LLC

